Corporate Overview

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2010 sales of $12.8 billion and has approximately 47,600 employees.

 

Business Overview

BioScience
2010 Sales-$5.7 Billion

Baxter is a leading manufacturer of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines.

Medical Products*
2010 Medication Delivery Sales-$4.8 Billion; 2010 Renal Sales-$2.4 Billion

Baxter’s Medical Products business manufactures products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, Baxter's Medical Products business is a leader in Renal home-based therapies, such as peritoneal dialysis, and offers other products and services for people with end-stage kidney disease.

*While the company operates in three reportable segments, in October 2010, the company combined its Medication Delivery and Renal businesses into a single global business unit, Medical Products.

2010 Sales by Business*

*While the company operates in three reportable segments, in October 2010, the company combined its Medication Delivery and Renal businesses into a single global business unit, Medical Products.

2010 Sales by Region

Regional Employee Breakdown

   

2008

2009

2010

United States  

20,600

20,600

19,000

Europe  

14,200

14,700

14,500

Latin America/Canada  

  7,050

  7,250

  7,050

Asia Pacific  

  6,600

  7,100

  7,000

Total  

48,450

49,700

47,600

R&D Expenditures (in millions)

Because of our longstanding commitment to research and development, Baxter’s history is rich with medical firsts, from the first commercially manufactured intravenous (IV) solutions to the first portable kidney dialysis machine, plus many more. Baxter continually pursues breakthrough technologies through research facilities around the world, and our investments reflect that commitment.